Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05139511
Other study ID # IPL-2020
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 15, 2021
Est. completion date August 15, 2023

Study information

Verified date October 2022
Source Vissum, Instituto Oftalmológico de Alicante
Contact Jorge Alió del Barrio, MD, PhD
Phone 965154062
Email jorge_alio@hotmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dry eye is often reported as the most common complication after a laser refractive surgery. Any refractive procedure can lead an impact on the corneal surface and the tear film. The main cause of this dry eye is the corneal denervation caused by the destruction of the anterior stromal nerves during the ablative procedure. This loss of corneal sensitivity leads to a decrease in the blink reflex, a decrease in the secretion rate of the meibomian glands and finally an evaporated dry eye. There is also a chronic inflammation at the corneal surface that produces an increase of inflammatory cytokines and a dysfunction of the meibomian glands. Yu et al have described incidences of dry eye closed to 60% after the first month of LASIK. Hovanesian et al have observed dry eye symptoms in 50% of patients 6 months after surgery. Donnenfeld et al describe 15% of moderate dry eye in the following 3 months and 5% of severe dry eye in the first 6 months. A small number of patients will present with chronic dry eye symptoms for more than 1 year. Bower et al analyzed its incidence in 0.8% Alterations in the tear film also decrease the quality of the retinal image and produce greater number of high-order due to the irregular. Pulsed light therapy (IPL) applied preoperatively in patients who undergo a laser refractive surgery may prevent the post-surgical dry eye and improve the refractive results. The aim of our study is to evaluate the usefulness of the applied therapy for the prevention of dry eye in patients that undergo a corneal refractive procedure.


Description:

1. Design Clinical experimental controlled trial, double-blind in which participants will be randomized into 2 groups: a study group (IPL + laser refractive surgery) and a control group (laser refractive surgery without IPL). The study will be conducted in accordance with Law 14/2007 of 3 July, on Biomedical Research, the Declaration of Helsinki (October 2013 version), standards of Good Clinical Practice and legislation in this area. All participants included in the study should read the Information Sheet and sign the informed and voluntary consent. 2. Participants Participants from Vissum Clinic that present the inclusion criteria and none of the exclusion criteria. The investigators will start the study with a preliminary project and depending on the results obtained, the investigators will apply these values to calculate the final sample size using the T-student-Fischer test for unilateral hypotheses and for a type 1 or α error of 5%. and a type 2 or β error of 20%. 3. Parameters evaluated Primary measures: age, sex, skin phototype, visual acuity with and without correction, refraction, cycloplegic refraction, OSDI and VAS questionnaire, use of artificial tears, oxford scale, lacrimal meniscus height, tear break-up time, conjunctival hyperemia, meibography and slit lamp examination. Secondary measures: corneal topography and tomography (MS-39, CSO, Italy), corneal aberrometry (MS-39, CSO, Italy), ocular aberrometry (Osiris, CSO, Italy), analysis of contrast sensitivity (CSV-1000, Vector vision), photographic capture of the epithelial defect in PRK, pre-surgical and postsurgical photographic capture of the eyelid changes in PRK. The measurement of the different objective variables will be carried out in the clinic. The measurement of the subjective variables will be carried out by two ophthalmologists, both masked. 4. Surgery and follow-up Participants who are candidates for a LASIK or SMILE procedure will receive, after randomization, IPL treatment in both eyes (experimental group) or sham IPL (control group). In the case of participant candidate for a PRK procedure, an intra-subject control group will be used, where one eye will receive the IPL treatment (right eyes) and the left contralateral eye the sham IPL treatment (control). Refractive surgeries will be performed exclusively two ophthalmologists following the same surgical protocol. IPL therapy (M22, Lumenis LTD, Israel) will be performed following the same protocol (standardized facial and periocular application with automatically adjusted energy according to Fitzpatrick skin classification). Three IPL sessions will be applied (simulated in the case of the control group): 7 days before the intervention, 7 days after the intervention, and 30 days after the intervention. The total postsurgical follow-up will be 6 months. 5. Statistical analyses All demographic and clinical data will be collected in a database and analyzed with the SPSS statistical package for Windows version 22.0. A p <0.05% will be considered significant.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date August 15, 2023
Est. primary completion date April 15, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria: - Patients over 18 years of age who are undergoing a corneal laser refractive surgery after a medical indication by the Vissum ophthalmologist Exclusion Criteria: - Pregnancy - Piercings - Fitzpatrick skin classification V and VI - Autoimmune diseases - Epilepsy - Previous history of herpes or ocular pathology - Pathological or suspicious corneal topography - Treatment in the previous month with corticosteroids, antihistamines or topical vasoconstrictors.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Study group
The IPL therapy consists in a polychromatic pulses of light not coherent and not collimated. The therapy leads to a series of processes such as the destruction of superficial blood vessels and thus the reduction of local inflammation, the liquefy of the meibum and an antimicrobial, anti-inflammatory and antioxidant effects. The therapy is performed over the cheeks, nose and upper eyelids.
Other:
Control group
Same procedure but without energy

Locations

Country Name City State
Spain Alicante Vissum Miranza Alicante

Sponsors (1)

Lead Sponsor Collaborator
Vissum, Instituto Oftalmológico de Alicante

Country where clinical trial is conducted

Spain, 

References & Publications (9)

Cote S, Zhang AC, Ahmadzai V, Maleken A, Li C, Oppedisano J, Nair K, Busija L, Downie LE. Intense pulsed light (IPL) therapy for the treatment of meibomian gland dysfunction. Cochrane Database Syst Rev. 2020 Mar 18;3:CD013559. doi: 10.1002/14651858.CD0135 — View Citation

Ge J, Liu N, Wang X, Du Y, Wang C, Li Z, Li J, Wang L. Evaluation of the efficacy of optimal pulsed technology treatment in patients with cataract and Meibomian gland dysfunction in the perioperative period. BMC Ophthalmol. 2020 Mar 18;20(1):111. doi: 10. — View Citation

Hovanesian JA, Shah SS, Maloney RK. Symptoms of dry eye and recurrent erosion syndrome after refractive surgery. J Cataract Refract Surg. 2001 Apr;27(4):577-84. — View Citation

Jung JW, Han SJ, Nam SM, Kim TI, Kim EK, Seo KY. Meibomian gland dysfunction and tear cytokines after cataract surgery according to preoperative meibomian gland status. Clin Exp Ophthalmol. 2016 Sep;44(7):555-562. doi: 10.1111/ceo.12744. Epub 2016 May 1. — View Citation

Nettune GR, Pflugfelder SC. Post-LASIK tear dysfunction and dysesthesia. Ocul Surf. 2010 Jul;8(3):135-45. Review. — View Citation

Rong B, Tang Y, Tu P, Liu R, Qiao J, Song W, Toyos R, Yan X. Intense Pulsed Light Applied Directly on Eyelids Combined with Meibomian Gland Expression to Treat Meibomian Gland Dysfunction. Photomed Laser Surg. 2018 Jun;36(6):326-332. doi: 10.1089/pho.2017 — View Citation

Solomon R, Donnenfeld ED, Perry HD. The effects of LASIK on the ocular surface. Ocul Surf. 2004 Jan;2(1):34-44. — View Citation

Toda I. Dry Eye After LASIK. Invest Ophthalmol Vis Sci. 2018 Nov 1;59(14):DES109-DES115. doi: 10.1167/iovs.17-23538. Review. — View Citation

Yu EY, Leung A, Rao S, Lam DS. Effect of laser in situ keratomileusis on tear stability. Ophthalmology. 2000 Dec;107(12):2131-5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary OSDI questionnaire It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology. 0 day
Primary Change from Baseline OSDI questionnaire It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology. 7 day
Primary Change from Baseline OSDI questionnaire It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology. 30 day
Primary Change from Baseline OSDI questionnaire It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology. 90 day
Primary Change from Baseline OSDI questionnaire It measures the severity of ocular surface symptoms and includes 12 items organized into 3 subscales; eye discomfort, functionality and environmental factors. After completing the questionnaire, a final score is obtained that when it is higher than 13 indicates ocular surface pathology. 180 day
Primary Lacrimal meniscus height Measured in millimeters by Ocular Keratograph 5M, a value greater than 0.20 mm is considered normal 0 day
Primary Change from Baseline Lacrimal meniscus height Measured in millimeters, a value greater than 0.20 mm is considered normal 7 day
Primary Change from Baseline Lacrimal meniscus height Measured in millimeters, a value greater than 0.20 mm is considered normal 30 day
Primary Change from Baseline Lacrimal meniscus height Measured in millimeters, a value greater than 0.20 mm is considered normal 90 day
Primary Change from Baseline Lacrimal meniscus height Measured in millimeters, a value greater than 0.20 mm is considered normal 180 day
Primary Tear Break-up-time Time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal. 0 day
Primary Change from Baseline Tear Break-up-time time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal. 7 day
Primary Change from Baseline Tear Break-up-time time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal. 30 day
Primary Change from Baseline Tear Break-up-time time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal. 90 day
Primary Change from Baseline Tear Break-up-time time elapsed from the last blink to the appearance of the first tear discontinuity measured by Ocular Keratograph 5M. A title longer than 5 seconds is considered normal. 180 day
Primary Conjunctival and ciliary hyperemia. Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe) 0 day
Primary Change from Baseline Conjunctival and ciliary hyperemia. Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe) 7 day
Primary Change from Baseline Conjunctival and ciliary hyperemia. Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe) 30 day
Primary Change from Baseline Conjunctival and ciliary hyperemia. Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe) 90 day
Primary Change from Baseline Conjunctival and ciliary hyperemia. Grade of red eye measured by Ocular Keratograph 5M. Jenvis ranking from 0 to 4 (normal, mild, moderate, severe) 180 day
Primary Upper and lower meibography Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification
Grade 0: no loss of meibomian glands.
Grade 1: loss of less than 1/3 of the total surface of the meibomian glands.
Grade 2: loss of 1/3 to 2/3 of the total area.
Grade 3: loss of more than 2/3 of the surface.
0 day
Primary Change from Baseline Upper and lower meibography Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification
Grade 0: no loss of meibomian glands.
Grade 1: loss of less than 1/3 of the total surface of the meibomian glands.
Grade 2: loss of 1/3 to 2/3 of the total area.
Grade 3: loss of more than 2/3 of the surface.
7 day
Primary Change from Baseline Upper and lower meibography Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification
Grade 0: no loss of meibomian glands.
Grade 1: loss of less than 1/3 of the total surface of the meibomian glands.
Grade 2: loss of 1/3 to 2/3 of the total area.
Grade 3: loss of more than 2/3 of the surface.
30 day
Primary Change from Baseline Upper and lower meibography Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification
Grade 0: no loss of meibomian glands.
Grade 1: loss of less than 1/3 of the total surface of the meibomian glands.
Grade 2: loss of 1/3 to 2/3 of the total area.
Grade 3: loss of more than 2/3 of the surface.
90 day
Primary Change from Baseline Upper and lower meibography Measured by Oculus Keratograph 5M. Observes and evaluates morphological changes of the meibomian glands Meiboscore classification
Grade 0: no loss of meibomian glands.
Grade 1: loss of less than 1/3 of the total surface of the meibomian glands.
Grade 2: loss of 1/3 to 2/3 of the total area.
Grade 3: loss of more than 2/3 of the surface.
180 day
Secondary Visual acuity Visual acuity with and without correction, measured on a decimal scale, determined by the Snellen panel, placing the examined person at a distance of 6 meters, will be collected by an optician. 0 day
Secondary Change from Baseline Visual acuity Visual acuity with and without correction, measured on a decimal scale, determined by the Snellen panel, placing the examined person at a distance of 6 meters, will be collected by an optician. 180 day
Secondary Corneal topography Performs an analysis of the cornea, which allows evaluating the shape and quantifying the power of the different curvatures 0 day
Secondary Change from Baseline Corneal topography Performs an analysis of the cornea, which allows evaluating the shape and quantifying the power of the different curvatures 180 day
Secondary Corneal aberrometry Technique that analyzes complex systems of light waves to quantify the set of optical aberrations that exist within the ocular structure. 0 day
Secondary Change from Baseline Corneal aberrometry Technique that analyzes complex systems of light waves to quantify the set of optical aberrations that exist within the ocular structure. 180 day
Secondary Analysis of contrast sensitivity Contrast Sensitivity is a test that assesses a person's ability to identify an object and separate it from the background Contrast sensitivity is evaluated with charts that can be used as projected or wall acuity charts. 0 day
Secondary Change from Baseline Analysis of contrast sensitivity Contrast Sensitivity is a test that assesses a person's ability to identify an object and separate it from the background Contrast sensitivity is evaluated with charts that can be used as projected or wall acuity charts. 180 day
Secondary VAS questionnaire investigates the intensity of the ocular surface symptoms from 0 to 100 (normal- severe) 0 day
Secondary Change from Baseline VAS questionnaire investigates the intensity of the ocular surface symptoms from 0 to 100 (normal- severe) 180 day
See also
  Status Clinical Trial Phase
Completed NCT05062564 - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye N/A
Completed NCT04884243 - Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction Phase 2
Active, not recruiting NCT04425551 - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction N/A
Terminated NCT02596919 - Fast Infrared Meibography (Photography) N/A
Completed NCT01207752 - The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction N/A
Completed NCT05162261 - to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction N/A
Recruiting NCT06064071 - Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD N/A
Completed NCT03652051 - A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED) Phase 2
Recruiting NCT03767530 - Efficacy and Safety of Thermic Devices in the Treatment of Meibomian Gland Dysfunction N/A
Active, not recruiting NCT05577910 - Vectored Thermal Pulsation, Intense Pulsed Light, and Eyelid Warm Compress Therapies for MGD N/A
Completed NCT04889950 - Clinical Study to Evaluate the Safety and Effectiveness of The Tixel Fractional System in the Treatment of Meibomian Gland Disfunction N/A
Recruiting NCT06004895 - Mechanisms of Light-based Therapies for Dry Eye Disease N/A
Completed NCT04147962 - Intense Pulsed Light in Meibomian Gland Dysfunctions
Completed NCT02256969 - Intraductal Meibomian Gland Probing Trial Phase 4
Recruiting NCT05089591 - Intense Pulsed Light in Meibomian Gland Dysfunction N/A
Completed NCT04500821 - Evaluation of the LipiFlow System With a New Activator N/A
Completed NCT03318874 - Optimization of the Treatment of Dry Eye Disease Caused by Meibomian Gland Dysfunction Phase 4
Completed NCT06278584 - iLux Treatment for Meibomian Gland Dysfunction N/A
Recruiting NCT04052841 - Morphological Analysis of Meibomian Glands N/A
Completed NCT05028491 - The Influence of Meibomian Gland Expression on Corneal Aberrations in MGD Patients